[Treatment of sight-threatening diabetic retinopathy]

Ugeskr Laeger. 2018 Jul 30;180(31):V11170870.
[Article in Danish]

Abstract

In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use
  • Diabetes Mellitus, Type 1 / complications
  • Diabetes Mellitus, Type 2 / complications
  • Diabetic Retinopathy* / drug therapy
  • Diabetic Retinopathy* / etiology
  • Diabetic Retinopathy* / prevention & control
  • Diabetic Retinopathy* / surgery
  • Humans
  • Intravitreal Injections
  • Laser Coagulation
  • Macular Edema* / drug therapy
  • Macular Edema* / etiology
  • Macular Edema* / prevention & control
  • Macular Edema* / surgery

Substances

  • Angiogenesis Inhibitors
  • Anti-Inflammatory Agents